Related Experiment Video
Updated: Aug 6, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor
Yingkun Xu1, Guandu Li2, Xinxiu Ren3
1Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China, qiluhospital.com.
Abstract:
Single-cell transcriptomics and machine learning methods are increasingly used to identify immune-related biomarkers in solid tumors, yet their combined application to microenvironment-related drivers of therapeutic resistance in clear cell renal cell carcinoma (ccRCC) is still limited. Here, we investigated the biological and clinical significance of myeloid-derived growth factor (MYDGF) through an integrative strategy spanning single-cell profiling, bulk multiomics, and functional validation. Analysis of scRNA-seq data (GSE156632) revealed that MYDGF is preferentially detected in malignant epithelial subpopulations and associated with the composition of myeloid and lymphoid compartments. Integration with TCGA-KIRC transcriptomic and clinical datasets demonstrated strong associations between MYDGF expression and immune-checkpoint activation, immune dysfunction signatures, and PI3K/AKT-MAPK pathway activity. Tumors with high MYDGF expression exhibited an immune-infiltrated yet functionally impaired microenvironment and were predicted to show reduced responsiveness to immune checkpoint blockade. Differential expression and enrichment analyses further highlighted MYDGF-associated genes involved in inflammatory, extracellular, and receptor-binding functions. A machine learning pipeline using LASSO Cox regression identified a preliminary 19-gene MYDGF-related prognostic gene set that requires further validation. Functional experiments confirmed that MYDGF knockdown suppressed proliferation, migration, and invasion in ccRCC cells. Overall, our analyses characterize MYDGF as a microenvironment-related biomarker linked to immune-associated features, signaling-associated alterations, and adverse prognosis in ccRCC. These results nominate MYDGF as a candidate prognostic biomarker and show the value of pairing single-cell resolution with computational modeling for biomarker discovery in renal cancer.
Insights
Myeloid-derived growth factor (MYDGF) is a potential biomarker in clear cell renal cell carcinoma (ccRCC). High MYDGF expression correlates with immune dysfunction and poor prognosis, suggesting therapeutic resistance in ccRCC tumors.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Clear cell renal cell carcinoma (ccRCC) treatment is challenged by therapeutic resistance.
- Understanding the tumor microenvironment is crucial for identifying resistance mechanisms.
Purpose of the Study:
- Investigate the role of myeloid-derived growth factor (MYDGF) in ccRCC.
- Identify MYDGF as a potential biomarker for immune-related resistance and prognosis in ccRCC.
Main Methods:
- Integrated analysis of single-cell RNA sequencing (scRNA-seq) and bulk multiomics data (TCGA-KIRC).
- Machine learning (LASSO Cox regression) for prognostic gene set identification.
- Functional validation of MYDGF in ccRCC cell lines.
Main Results:
- MYDGF is expressed in malignant epithelial cells and linked to myeloid/lymphoid cell composition.
- MYDGF expression correlates with immune-checkpoint activation, immune dysfunction, and PI3K/AKT-MAPK signaling.
- High MYDGF tumors show immune infiltration but impaired function, predicting poor response to immunotherapy.
- MYDGF knockdown inhibits ccRCC cell proliferation, migration, and invasion.
Conclusions:
- MYDGF is a significant biomarker associated with immune microenvironment alterations, signaling pathways, and adverse prognosis in ccRCC.
- MYDGF may serve as a prognostic biomarker and therapeutic target in ccRCC.
- Combining single-cell resolution with computational modeling is valuable for ccRCC biomarker discovery.